{
  "docId": "019de073-d546-7099-b69b-fc409bd054ba",
  "docSlug": "a8472da99eed55bdf1e59eb3c42372d9",
  "documentTitle": "Silo Pharma | Investor Presentation Deck | 24 slides",
  "authorId": "silo-pharma",
  "authorName": "Silo Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 24,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide outlines a specific pharmaceutical asset (SPC-15) and its market context.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de073-d546-7099-b69b-fc409bd054ba/13",
  "deckHref": "/decks/019de073-d546-7099-b69b-fc409bd054ba",
  "deckJsonHref": "/decks/019de073-d546-7099-b69b-fc409bd054ba.json",
  "deckAnchorHref": "/decks/019de073-d546-7099-b69b-fc409bd054ba#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.1,
        "x": 0.87,
        "y": 0.04
      },
      "kind": "image",
      "text": "SiloPharma",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7720c57a-6e76-4dad-aa9e-0a78c5c9dd7e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.3,
        "x": 0.65,
        "y": 0.23
      },
      "kind": "list",
      "text": "Applications. Sponsored research agreement with Columbia University. Prevention of stress-induced affective disorders. Increasing stress resilience in military, first responders, and other populations at high risk of PTSD. Predicting level of severity or progression of such disorders. Molecular targets for use in drug discovery of innovative treatments",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "60eb3142-2bf5-47b5-a288-5f9f3ceb2705",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.34,
        "y": 0.23
      },
      "kind": "list",
      "text": "Market Opportunity: Stress-induced Affective Disorders. 26% of Americans 18+ suffer from anxiety, PTSD and other disorders. This number has escalated post-COVID-19. U.S. market for relevant drugs expected to reach $13 billion by 2027",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "667eb4f2-74a4-4ecd-a5cf-4b7dd974afa3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.25,
        "x": 0.34,
        "y": 0.67
      },
      "kind": "list",
      "text": "Technology. Metabolomic biomarkers predict response to pharmacological treatments. Utilizes ketamine compositions as a method for treatment and prevention",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b8bdbe30-a497-414b-8006-b124431e3546",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.25,
        "x": 0.05,
        "y": 0.32
      },
      "kind": "title",
      "text": "SPC-15 Targeted Prophylactic Treatment—Stress-Induced Affective Disorders",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "36713e32-a0b3-4754-b5c5-f235bd397cbb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.35,
        "x": 0.107,
        "y": 0.065
      },
      "kind": "title",
      "text": "Columbia University CELA",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "73e5911d-4489-4b40-813d-c34b493b87fe",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 9,
      "beatId": "7eef8438-24a9-41be-8257-c3233f0d4ebf",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The solution is presented in the Zylö Therapeutics Joint Venture and UMB License Agreement sections",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 13,
      "from": 12,
      "name": "Voice Of Customer",
      "slug": "51-voice-of-customer",
      "bestFor": "Product strategy, customer experience, market research",
      "matchId": "94f0c355-ccb6-4143-8394-ffb96a1ebac7",
      "evidence": "The deck presents SPC-14 and SPC-15 as solutions for these conditions",
      "position": 0,
      "objective": "To understand the needs of patients with Alzheimer's and stress-induced affective disorders",
      "structure": "What Customers Say (Verbatim) -> The Pattern Across Voices -> The Insight -> The Response",
      "confidence": 0.6,
      "description": "Let customer quotes and feedback drive the narrative and validate the insight"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}